In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Titan Pharmaceuticals Inc.

http://www.titanpharm.com

Latest From Titan Pharmaceuticals Inc.

Gilead Keeps Close Eye On Stormy Remdesivir Situation In India

Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.

Commercial Coronavirus COVID-19

India Remdesivir Saga: Exports Barred, Ramp Up Plans And Panic

India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral take multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.

Policy & Regulation Coronavirus COVID-19

India Remdesivir Saga: Exports Barred, Ramp Up Plans And Panic

India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral progress multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.

India Policy & Regulation

Zydus Claims Exclusivities After A Pair Of US Approvals

Zydus Cadila has claimed eligibility for periods of 180-day exclusivity linked to two of its recent US generic approvals, for rivals to Imbruvica and Opsumit.

Approvals Generic Drugs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Medical Devices
    • Implantable Devices
  • Other Names / Subsidiaries
    • Titan
UsernamePublicRestriction

Register